

Diabetes Case Studies: Navigating the Alphabet Soup of Treatment Options

AAPA 2020

Ashlyn Smith, PA-C

Endocrinology Associates, Scottsdale, AZ

President, American Society of Endocrine Physician Assistants

ashlyns9@endoassocaz.net

Medication reference list

- **Glucagon-like peptide-1 receptor agonist (GLP-1 RA)**
 - Liraglutide (Victoza)
 - Semaglutide injection (Ozempic)
 - Oral semaglutide (Rybelsus)
 - Dulaglutide (Trulicity)
 - Exenatide (Byetta)
 - Exenatide weekly (Bydureon/BCise)
- **Sodium-glucose linked cotransporter 2 inhibitor (SGLT2i)**
 - Empagliflozin (Jardiance)
 - Canagliflozin (Invokana)
 - Dapagliflozin (Farxiga)
 - Ertugliflozin (Steglatro)
- **Sulfonylureas (SU):** glimepiride, glipizide, glyburide
- **Thiazolidinedione (TZD):** pioglitazone (Actos)
- **Dipeptidyl peptidase-4 inhibitor (DPP4i)**
 - Sitagliptin (Januvia)
 - Saxagliptin (Onglyza)
 - Linagliptin (Tradjenta)
 - Alogliptin (Nesina)
- **Basal insulins:**
 - Degludec u-100/u-200 (Tresiba)
 - Glargine u-300 (Toujeo)
 - Glargine u-100 (Lantus or Basaglar)
 - Detemir u-100 (Levemir)
- **Intermediate insulin:** NPH (Humulin N, Novolin N)
- **Basal insulin/GLP-1 RA combos**
 - insulin glargine/lixisenatide (Soliqua)
 - insulin degludec/liraglutide (Xultophy)

DM Meds with additional indications

- GLP-1 RA:

- **Liraglutide:** reduce the risk for major adverse cardiovascular events (MACE: MI, stroke, and CV death) in adults with Type 2 DM and known CVD
- **Semaglutide injection:** reduce the risk of MACE in adults with Type 2 DM and known CVD
- **Dulaglutide:** reduce the risk of MACE in adults with Type 2 DM and known CVD or multiple cardiovascular risk factors

- SGLT2i:

- **Empagliflozin:** reduce the risk of CV death in adults with Type 2 DM and known CVD
- **Canagliflozin:**
 - Reduce the risk of MACE in adults with Type 2 DM and known CVD
 - Reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, CV death, and hospitalization for heart failure (HF) in adults with Type 2 DM and diabetic nephropathy with albuminuria >300 mg/day
- **Dapagliflozin:** reduce the risk of hospitalization for HF in adults with Type 2 DM and known CVD or multiple cardiovascular risk factors